Jacobio Pharmaceuticals Sets 2026 AGM, Seeks Fresh Share Issuance Mandate

Jacobio Pharmaceuticals Group Co., Ltd. ( (HK:1167) ) has shared an update.

Jacobio Pharmaceuticals has called its 2026 annual general meeting for June 5, 2026, in Beijing, where shareholders will review and adopt the company’s audited financial statements and directors’ and auditor’s reports for the year ended December 31, 2025. The agenda also includes the re-election of three directors, re-appointment of Deloitte Touche Tohmatsu as auditor, and approval of a general mandate allowing the board to issue up to 20% of the company’s share capital, providing management with added flexibility for future financing and strategic corporate actions.

These resolutions, if approved, will maintain continuity in the company’s leadership and external audit oversight, while equipping the board with expanded authority to raise equity or execute capital market transactions. The share issuance mandate, excluding rights issues, convertible securities, warrants, option schemes and scrip dividends, could influence future capital structure decisions and potential dilution, and signals the company’s intent to preserve financial agility in a competitive pharmaceutical sector.

The most recent analyst rating on (HK:1167) stock is a Buy with a HK$10.34 price target. To see the full list of analyst forecasts on Jacobio Pharmaceuticals Group Co., Ltd. stock, see the HK:1167 Stock Forecast page.

More about Jacobio Pharmaceuticals Group Co., Ltd.

Jacobio Pharmaceuticals Group Co., Ltd. is a Hong Kong-listed biopharmaceutical company focused on the research, development and commercialization of innovative pharmaceutical products. The group operates primarily in mainland China and targets both domestic and international markets through oncology and other specialty therapies.

Average Trading Volume: 3,313,681

Technical Sentiment Signal: Strong Buy

Current Market Cap: HK$5.79B

For a thorough assessment of 1167 stock, go to TipRanks’ Stock Analysis page.